UDPATE: Jefferies Downgrades BioSante Pharma to Hold

Loading...
Loading...
Jefferies & Company has published a research report on BioSante Pharmaceuticals
BPAX
downgrading the company from Buy to Hold and lowering the price target from $5 to $0.70. In the report, Jefferies writes, "BPAX announced top-line LibiGel Ph III data, and in a surprise, missed on all 6 efficacy endpoints. Given the magnitude of the miss, the LibiGel story seems to be done; thus we now remove all LibiGel-related revenue from our model. BPAX still has cash (estimated runway to mid-'13) and a Feb '12 catalyst w/ Bio-T-Gel's PDUFA, so the story's not over yet." BioSante Pharmaceuticals closed yesterday at $2.12.
Posted In: Analyst ColorDowngradesPrice TargetPre-Market OutlookAnalyst RatingsJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...